Effectiveness of recombinant human interferon-α2b vaginal effervescent tablets combined with microwave therapy for chronic cervicitis combined with persistent high-risk HPV infection
OBJECTIVE To investigate the clinical effectiveness of recombinant human interferon-α2b(IFN-α2b)combined with microwave therapy for chronic cervicitis(CC)complicated with persistent high-risk human papillo-mavirus(HR-HPV)infection and the effect on immune balance.METHODS 106 patients with CC complicated with persistent HR-HPV infection admitted to Anqing First People's Hospital from Jan.2021 to Dec.2022 were selected and randomly divided into the control group and the study group according to the method of random num-ber table.The control group was treated with microwave therapy,while the study group was given IFN-α2b vagi-nal effervescent tablets combined treatment on the basis of the control group,both of which were treated for 3 months.The clinical effectiveness,HPV seroconversion rate,improvement time of clinical symptoms,levels of immune and inflammatory markers before and after treatment,and incidence of adverse events during treatment between two groups were compared.RESULTS The total effective rate of the study group was 79.25％,which was higher than that of the control group(P＜0.05);After treatment,the negative conversion rates of HPV types 16 and 18 in the study group were 72.41％and 79.17％,respectively,which were higher than those in the control group(P＜0.05);The wound healing time(42.17±10.25)days,scab removal time(7.24±1.60)days,and vaginal drainage time(6.78±0.53)days in the study group were all shorter than those in the control group(all P＜0.05);The CD4+(36.50±5.74)％and CD4+/CD8+(1.51±0.34)of the study group were higher than those of the control group(P＜0.05),while the CD8+(21.87±3.75)％was lower than that of the control group(P＜0.05);The levels of interleukin-10(IL-10),C-reactive protein(CRP),and tumor necrosis factor al-pha(TNF-α)in the study group were lower than those in the control group(P＜0.05);There was no statistically significant difference in the incidence of adverse events between the two groups(13.21％vs.5.66％).CONCLUSION The combination of recombinant human interferon a-2b and microwave therapy effectively improved the CD4+/CD8+immune balance and promoted HPV seroconversion in patients with CC and persistent HR-HPV infection.
Chronic cervicitisHigh-risk human papillomavirusRecombinant human interferon-α2bMicrowave therapyCD4+/CD8+Immune balanceInflammatory marker
万方数据
维普
